- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
New Phase 3 Findings Show STELARA® Significantly Reduced Signs And Symptoms Of Active Psoriatic Arthritis
STELARA Continued to Provide Benefit in Psoriatic Arthritis Signs and Symptomsthrough Week 52 in One Phase 3 Trial
Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression In Patients With Active Rheumatoid Arthritis
Patients Receiving Intravenous Golimumab Showed Significant Improvements inSigns and Symptoms of Rheumatoid Arthritis through One Year According to New Study Findings
Johnson & Johnson Family of Diabetes Companies Provides Diabetes Supplies to Children in Developing Countries
LifeScan, Inc. supplies one million test strips and encourages support for International Diabetes Federation’s Life for a Child program
FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events
XARELTO® Has the Broadest Indication Profile of Any New Oral Anticoagulant
New One-Year Phase 3 Study Results Show Anti-Tnf SIMPONI® Maintained Clinical Response In Treatment Of Moderately To Severely Active Ulcerative Colitis
Data Demonstrate Remission and Mucosal Healing with SIMPONI Maintenance Therapy
Crohn’s Disease Patients Refractory To Tumor Necrosis Factor Inhibitors Showed Improvement In Disease With STELARA® Treatment
STELARA Phase 2b Crohn’s Disease Study Published in The New England Journal of Medicine